Nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2

Frontiers in Oncology - Switzerland
doi 10.3389/fonc.2018.00253

Related search